CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Site Search
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
When considering making a change to your health insurance coverage or enrolling in a plan, it is important to know about the annual open enrollment period and when those changes can be made.
Understanding insurance basics and knowing what to look for when choosing new health coverage can help you get a plan that best suits your individual needs.
The Cystic Fibrosis Foundation, alongside the CF community, urges Congress to pass the PASTEUR Act and the HELP Copays Act.
From budgeting for the everyday, to triaging the unexpected and dreaming of the future, there is a lot to consider when building a financial plan. While living with cystic fibrosis may be costly, financial planning can help ease some of the stress you may feel so you can focus on other areas of your life.
Scientists around the world agree that global innovation is needed to address the shortage of effective antibiotics. Our Infection Research Initiative supports much-needed research and development, but new policies are needed to promote a sustainable, robust antibiotics pipeline and a marketplace that rewards innovation.
People living with cystic fibrosis may apply for Social Security Disability Insurance or Supplemental Security Income, programs that serve as a source of income and health insurance coverage for people who are unable to work due to their health status.